Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2026)

Keros Therapeutics (KROS) has 7 years of Accumulated Expenses data on file, last reported at $16.0 million in Q4 2025.

• Quarterly Accumulated Expenses fell 23.15% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (down 23.15% YoY) and the FY2025 annual result came in at $16.0 million, down 23.15% from the prior year.
• Accumulated Expenses improved to $16.0 million in Q4 2025, from $15.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $22.2 million in Q3 2024 to a low of $5.5 million in Q1 2021.
• A 5-year average of $12.6 million and a median of $12.5 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses soared 87.71% — and 2025, when it plunged 31.55%.
• Tracing KROS's Accumulated Expenses over 5 years: stood at $7.3 million in 2021, then jumped by 73.77% to $12.8 million in 2022, then soared by 40.5% to $17.9 million in 2023, then grew by 16.48% to $20.9 million in 2024, then fell by 23.15% to $16.0 million in 2025.
• The last three Accumulated Expenses figures came in at $16.0 million (Q4 2025), $15.2 million (Q3 2025), and $20.0 million (Q2 2025), per Business Quant data.